NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
TORONTO, Sept. 27, 2018 — Canada House Wellness Group Inc. (CSE: CHV) (“Canada House” or the “Company” – CSE:
CHV) is pleased to announce the immediate granting of 1,500,000 stock options to the President of its wholly owned
subsidiary Abba Medix Corp. (“Abba”), a licensed cannabis producer under the Access to Cannabis for Medical Purposes
Regulations (the “ACMPR”), pursuant to the Company’s stock option plan. The stock options vest in 3 equal tranches based
on Abba’s receipt of a full sales license of dried cannabis flower under the ACMPR, the completion of Abba’s premium indoor
controlled production facility, and the completion of Abba’s first full cannabis harvest.
Scott Purdy, Chairman of the Board of Canada House, commented, “We are grateful for Riley’s continuing diligence, hard
work, and dedication to Abba and Canada House as we work towards achieving several important milestones for the
Canada House Wellness Group Inc.
Canada House is an experienced, integrated medical cannabis company providing patient-specific cannabinoid therapy
products and services through its clinics and licensed producer. Canada House is the parent company of Marijuana for Trauma
Inc., Knalysis Technologies and Abba Medix Corp. For more information please visit www.canadahouse.ca or www.sedar.com.
For further information, please contact:
Boom Capital Markets
Canada House Wellness Group Inc.
Chris Churchill-Smith, CEO
Cautionary Statement Regarding Forward Looking Information. This press release contains forward-looking statements,
including statements that relate to, among other things, the Company’s clinic, production and technology businesses, its
future plans, the Company’s markets, objectives, goals, strategies, intentions, beliefs, expectations and estimates, and can
generally be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”,
“intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” (or the negative thereof) and words and
expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking
statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on
such statements. Certain material factors or assumptions are applied in making forward-looking statements, and actual
results may differ materially from those expressed or implied in such statements. Material assumptions used to develop
forward-looking information in this news release include, among other things, the regulations related to cannabis use under the
Access to Cannabis for Medical Purposes Regulations and the act respecting cannabis and to amend the Controlled Drugs
and Substances Act, the Criminal Code and other Acts, passed by the Canadian Federal government, making cannabis legal
for recreational use by October 17, 2018; Company liquidity and capital resources, including the availability of additional
capital resources to fund its activities; level of competition; the ability to adapt products and services to the changing market;
the ability to attract and retain key executives; and the ability to execute strategic plans. Additional information about material
factors that could cause actual results to differ materially from expectations and about material factors or assumptions
applied in making forward-looking statements may be found in the Company’s most recent annual and interim Management’s
Discussion and Analysis under “Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian
securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any of the
forward-looking statements contained in this document, whether as a result of new information, future events or otherwise,
except as required by law.”
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.